-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Good news! Shijiazhuang No.4 Pharmaceutical has once again made the list of China’s Top 100 Pharmaceutical Companies.
Category:
Time：2022-12-18
On December 18, the 2022 (39th) National Pharmaceutical Industry Information Conference, hosted by the China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology, was held in Shanghai. During the conference, several highly anticipated industry rankings were released, including the 2021 Top 100 Chinese Pharmaceutical Companies List. Shijiazhuang Sihua Pharmaceutical Co., Ltd. was honored to be listed on the 2021 Top 100 Chinese Pharmaceutical Companies, ranking 59th—up 13 places from the previous year. Additionally, the company has been awarded the title of “Best Pharmaceutical R&D Product Line Enterprise in China 2022” for the third consecutive time.
On December 18, the 2022 (39th) National Pharmaceutical Industry Information Conference, hosted by the China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology, was held in Shanghai. During the conference, several highly anticipated industry rankings—including the 2021 Top 100 Chinese Pharmaceutical Companies List—were released. Shijiazhuang Sihua Pharmaceutical Co., Ltd. was honored to be listed on the 2021 Top 100 Chinese Pharmaceutical Companies, ranking 59th, a rise of 13 places from the previous year. Additionally, the company has been awarded the title of “Best Pharmaceutical R&D Product Line Enterprise in China 2022” for the third consecutive time.
Over the past two years, Shijiazhuang No.4 Pharmaceutical has fully leveraged its scale advantages, quality strengths, and brand reputation by aligning its innovation efforts with the industrial chain. The company has accelerated the research and development of specialized generic drugs, active pharmaceutical ingredients, innovative drugs, pharmaceutical packaging materials, and products undergoing consistency evaluations. It has established a tiered chemical drug R&D system—“developing a batch, translating another batch, and reserving a third”—achieving synchronized advancement across the entire drug R&D and market-translation value chain. As a result, the company has forged a uniquely distinctive product portfolio layout and gained new competitive advantages in the industry. The continuous optimization of its product structure and ongoing enhancement of its industrial chain have provided strong support for Shijiazhuang No.4 Pharmaceutical to improve quality, boost efficiency, and achieve rapid growth, effectively propelling the company toward the high-end segments of the value chain. Over the past two years, the company’s core business volume and revenue have continued to grow, with operating results repeatedly hitting new highs, marking significant breakthroughs in its high-quality development and positioning it among the leaders in the domestic industry.
It is reported that the “Annual Top 100 Chinese Pharmaceutical Companies” selection, undertaken by the China Pharmaceutical Industry Information Center under the Ministry of Industry and Information Technology of China, is the most authoritative and socially influential professional evaluation event in China’s pharmaceutical industry. The selection is based on three key indicators—total assets of pharmaceutical enterprises, main business revenue, and total profits—and ranks companies according to their status as legal entities of industrial enterprises (including those with consolidated financial statements). This selection enjoys high authority and guidance, and has attracted widespread attention from pharmaceutical companies, the industry, and society at large.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license